Unprovoked internal jugular vein thrombosis: a case report and literature review

Loïc Payrard¹, Léa Iten¹, Jacques Donzé¹,²,³ and Gregor John¹,⁴*

Abstract

**Background:** Managing thrombosis in rare sites is challenging. Existing studies and guidelines provide detailed explanations on how to overcome lower-limb thromboses and pulmonary embolisms, but few studies have examined thrombosis in rare sites. Lack of data makes clinical practice heterogeneous. Recommendations for diagnosing, treating, and following-up internal jugular vein thrombosis are not clearly defined and mostly based on adapted guidelines for lower-limb thrombosis.

**Case presentation:** A 52-year-old Caucasian woman came to the Emergency Department with chest, neck, and left arm pain. Computed tomography imagery showed a left internal jugular vein thrombosis. An extensive workup revealed a heterozygous factor V Leiden gene. Therapy was initiated with intravenous unfractionated heparin, then switched to oral acenocoumarol, which resolved the symptoms. Based on this case presentation and a literature review, we summarize the causes, treatment options, and prognosis of unprovoked internal jugular vein thrombosis.

**Conclusions:** Managing internal jugular vein thrombosis lacks scientific data from large randomized clinical trials, partly because such thromboses are rare. Our literature review suggested that clinical treatments for internal jugular vein thrombosis often followed recommendations for treating lower-limb thrombosis. Future specific studies are required to guide clinicians on the modalities of diagnosis, screening for thrombophilia or oncologic disease, treatment duration, and follow-up.

**Keywords:** Internal jugular vein, Thrombosis, Thrombophilia, Unprovoked

Background

Thromboembolic disease is the third most frequent cardiovascular disease [1]. It has been thoroughly studied in recent decades, resulting in a standard diagnostic strategy, international guidelines, and new medications [2, 3].

There is scarce medical literature available on unprovoked internal jugular vein (IJV) thrombosis, essentially just case reports and short case series. IJV thrombosis is, therefore, often managed with reference to guidelines dedicated to thromboses occurring in more common sites, notably the deep veins of the lower limbs [2, 3]. Yet unusual thrombosis sites are associated with distinct risk factors and complications, and some treatments (e.g. direct oral anticoagulants) have not been tested specifically. Thus, we believe that specific recommendations are needed to guide the treatment management of patients with thromboses in uncommon sites.

This report describes a case of unprovoked IJV thrombosis and an accompanying literature review about diagnosing and treating this condition.

**Case presentation**

A 52-year-old Caucasian woman under treatment for hypothyroidism arrived at the Emergency Department with...
constrictive chest pain that had been radiating into her left arm and cervical region for 1 week, accompanied by new-onset dyspnea which had worsened 2 days before her medical visit. Her physical examination was unremarkable, except for high blood pressure (188/104 mmHg) and excess weight (body mass index = 28 kg/m2); a blood test showed a high D-dimer concentration (2170 μg/l). A computed tomography (CT) scan performed to exclude pulmonary embolism was inconclusive. However, fat infiltration around the left jugular-carotid led to a further investigation using neck ultrasound. This showed a thrombosis emerging from the base of the left subclavian vein and extending 11 centimeters into the IJV, sparing the cerebral vessels.

The patient described spontaneous hair loss and a 10 kg gain in weight over the previous year. She was taking levothyroxine but took no other medication or hormonal substitutes. There was no history of smoking, recent surgery, trauma, infectious disease, intravenous medical or recreational drug use, or past catheter insertion.

A chest CT scan and a colonoscopy revealed no cancer. A recent gynecological check-up consisting of a physical examination, a mammography, and a Pap smear found no pathology. A thyroid-stimulating hormone test and urinary cortisol were normal. Because of the patient’s young age and no obvious risk factor for thromboembolic disease, we completed the investigations with a thrombophilia workup. Antinuclear antibodies were positive at 1:320, but without other criteria suggesting overt lupus [4]. Otherwise, antinucleoprotein antibodies (SSA, SSB, RNP, Sm, Sc170, Jo1), antinucleosome antibodies, anticardiolipin antibodies, and anti-B2-glycoprotein antibodies were negative. We did not test for lupus anticoagulant due to the patient’s anticoagulation treatment and the risk of a false-positive [5]. Anti-thrombin, protein C, and protein S activity were within the normal ranges and were tested before the introduction of anticoagulant treatment. Only a heterozygous factor V Leiden gene (RS56Q) was found positive. We concluded on the diagnosis of an unprovoked IJV thrombosis.

After 5 days of intravenous unfractionated heparin, symptoms rapidly regressed, allowing a switch to an oral anticoagulant (acenocoumarol). The patient was discharged home 1 week after admission. After 3 months, the decision to continue anticoagulation with acenocoumarol was taken according to European Society of Cardiology guidelines [2] for patients over 50 years old with unprovoked thrombosis and a low risk of major bleeding (HAS-BLED score for major bleeding risk = 1 due to hypertension, corresponding to a 3.4% risk [6]). 6 months after Emergency Department admission, the patient was symptom-free.

Discussion and conclusions
We have described a patient presenting with unprovoked IJV thrombosis, heterozygous factor V Leiden gene, and no other obvious risk factors. This rare thrombosis site reveals the limits of international guidelines based on large, randomized clinical trials mainly designed for deep-vein thrombosis in a limb or pulmonary embolism. There is, therefore, a lack of evidence which might guide clinicians in their workup and treatment of thrombosis in rare sites. Although, by their very nature, published case reports and case series provide biased information, exploring similar cases can be a first step (and sometimes the only one possible) towards collecting scientific evidence.

Medline research strategy
We searched Medline using the keywords (spontaneous OR unprovoked OR idiopathic OR primary AND internal jugular vein thrombosis AND English) and excluded reports of provoked IJV thrombosis to collect information on causes, treatment modalities, and complications. We retrieved 40 relevant articles in English (Table 1). These articles included 48 patients with unprovoked IJV from 17 countries, but mostly from Japan (9/40 articles). More than a third (17/48; 35%) were still truly idiopathic after the workup (Table 2).

Internal jugular vein thrombosis epidemiology
Upper-limb thrombosis accounts for a maximum of 10% of all deep-vein thromboses [2, 47]. IJV thrombosis is even less frequent, but epidemiological studies are lacking (other unusual sites for thrombosis, such as the mesenteric vein, account for 0.002–0.006% of all inpatient admissions) [48]. Overall, the most common causes of IJV thrombosis are cancer, central venous catheter placement, and ovarian hyperstimulation syndrome (OHS) [26]. IJV thrombosis can be provoked or unprovoked. The former accounts for four out of five cases [26]. Most IJV thromboses are secondary to central catheter or pacemaker placement, extrinsic compression (by a tumor or malformation), local infections (e.g., Lemierre disease), cervical trauma, or ENT cancer. Unprovoked IJV thrombosis is uncommon and has been associated with paraneoplastic disease, thrombophilia, OHS, and idiopathic IJV [10, 26, 49–51]. OHS is associated with thromboembolic complications, but their mechanisms are incompletely understood [52]. In addition to the usual hemostatic changes during pregnancy [53], OHS can cause increased levels of coagulation factors [54].

Clinical presentation
The spectrum of potential clinical presentations is broad, ranging from asymptomatic disease to diffuse and non-specific pain. Neck pain and swelling are the most frequent symptoms, found in 24/48 patients (50%). IJV thrombosis is a serious event, with a potentially fatal outcome, but complications in IJV thrombosis have seldom been reported [55]. Pulmonary embolism was reported in 3 cases (6%). Surprisingly, there were no cases describing
| Author, journal, year [ref] | Country       | Nb* | Age (F/M) | Thrombosis location | Associated factors | Imaging | Symptoms                          | Treatment (type and length)                          | Complication |
|----------------------------|---------------|-----|-----------|---------------------|-------------------|---------|-----------------------------------|------------------------------------------------------|--------------|
| Payrard et al. 2020        | Switzerland   | 1   | 52       | F                   | Left UV           | US + CT | Painful neck swelling             | Intravenous heparin for 5 days and acenocoumarol prolonged | /            |
| Algobian et al., Cureus, 2020 [7] | Saudi Arabia | 1   | 66 M     | Right UV, subclavian and axillary vein | Liver transplant | US + CT | Right chest, flank and back pain | Enoxaparin 1 mg/kg twice daily                        | /            |
| Pratt et al., J Thromb Thrombolysis, 2020 [8] | USA           | 1   | 21 F     | Left UV, transverse and sigmoid sinus | Nitrous oxide abuse | MRI     | Confusion, hallucinations, weakness and falls | LMWH (duration not describe)                         | /            |
| Agrawal et al., Cureus, 2019 [9] | USA           | 1   | 64 F     | Right UV and subclavian vein | /                  | US      | Right upper extremity and right facial swelling | Intravenous heparin for 2 days and Apixaban for 6 months | /            |
| Hahn et al., Auris Nasus Larynx, 2019 [10] | Germany       | 3/41* | 50, 54, 78 | Internal jugular vein (side not describe) | 3 idiopathic, 22 paraneoplastic (compression and distant disease), 14 inflammatory diseases, 2 central-venous catheter | US + CT | Asymptomatic                       | Apixaban 5 mg (duration not describe) / Rivaroxaban 20 mg for 2 months / Rivaroxaban for 3 months | /            |
| Matsuda et al., eNeurologicalSci, 2018 [11] | Japan         | 1   | 71 M     | Right UV           | Pseudotumor cerebri and Lung cancer | Veinography + US | Not describe                             | Warfarin, 3 mg/day                                 | /            |
| Al-Zoubi, Vasc Health Risk Manag, 2018 [12] | Jordan        | 1   | 44 F     | Right UV           | Antiphospholipid syndrome | US + CT | Painful neck swelling             | LMWH for 3 months and long-term warfarin             | /            |
| Jendoubi, Saudi J Anaesth, 2017 [13] | Saudi Arabia  | 1   | 75 M     | Right UV           | /                  | US      | Exacerbation of COPD             | Not describe                                        | Pulmonary embolism                                  |            |
| Toratani et al., Intern Med, 2017 [14] | Japan         | 1   | 45 M     | Left UV, subclavian and brachiocephalic vein | Gastric cancer | US + CT | Swelling of the left side of his neck and left upper limb | Unfractionated heparin for 7 days and long-term Edoxaban (60 mg/day, orally) | /            |
| Nomura et al., Intern Med, 2016 [15] | Japan         | 1   | 70 F     | Left UV           | /                  | CT      | Dyspnea                          | Anticoagulation therapy for 2 weeks                  | Pulmonary embolism                                  | /            |
| Bandara et al., J Med Case Rep, 2016 [16] | Sri Lanka     | 1   | 75 M     | Left UV, external jugular and brachiocephalic vein | Prostate carcinoma | US + CT | Painless swelling of the left supravacular fossa | Intravenous heparin and long-term oral warfarin | /            |
| Efe et al., Perfusion, 2015 [17] | Turkey        | 1   | 19 F     | Right UV           | /                  | US + CT + MRI | Pain and swelling of the right side of the neck | Enoxaparin and warfarin for 6 months | /            |
| Author, journal, year [ref] | Country | Nb* | Age | Gender (F/M) | Thrombosis location | Associated factors | Imaging | Symptoms | Treatment (type and length) | Complication |
|-----------------------------|---------|-----|-----|--------------|---------------------|-------------------|---------|----------|-----------------------------|--------------|
| Onishi et al., Case Rep Nephrol Dial, 2015 [18] | Japan | 1 | 56 | M | Left UV and subclavian vein | Nephrotic syndrome | CT | Swelling of the upper limb | Heparin and warfarin (duration not describe) | / |
| Van den Broek et al., Neth J Med, 2014 [19] | Netherlands | 1 | 28 | F | Right UV | Borderline ovarian tumour | US + MRI | Mass in the right neck | Tinzaparin 0.9 ml daily (duration not describe) | / |
| Altintas et al., Case Rep Vasc Med, 2014 [20] | Turkey | 1 | 42 | F | Bilateral UV | Inherited coagulopathy (homozygous MTHFR mutation and protein C deficiency) | US + MRI | Asymptomatic | LMWH and long-term warfarin | Recurrent thrombosis (lower limb DVT) |
| Ghatak et al., J Anaesthesiol Clin Pharmacol, 2013 [21] | India | 1 | 21 | F | Right UV and subclavian vein | Homozygous Factor V Leiden mutation, activated factor C resistance and Dengue infection | US | Septic shock and encephalopathy | Unfractionated heparin and warfarin (duration not describe) | / |
| Papay et al., J Crohns Colitis, 2013 [22] | Austria | 1/157a | NA | NA | UV (side not describe) | Inflammatory bowel disease | Not describe | Not describe | Not describe | Recurrent thrombosis (venous arm thrombosis) |
| Kunimasa et al., Intern Med, 2013 [23] | Japan | 1 | 70 | F | Left UV | Lung cancer (Trousseau's syndrome) | CT | Painful swelling left side of the neck | Not describe | / |
| Honma et al., J Echocardiogr, 2011 [24] | Japan | 1 | 59 | F | Left internal jugular vein | / | US + CT | Dizziness | Oral warfarin (duration not describe) | / |
| Ishida et al., J Neurosurg Spine, 2011 [25] | Japan | 1 | 56 | F | Left internal jugular vein | Cervical spontaneous spinal epidural hematoma | MRI + Angiography | Pain of the back of the head and neck | / (because of the hematoma) | / |
| Gbaguidi et al., QJM, 2011 [26] | France | 5/29a | NA | NA | 18/29 Left UV 7/29 Right UV 4/29 Bilateral UV | 24/29: secondary UV 5/29: idiopathic UV | US + CT | Cervical oedema, arm oedema, pain, erythrocyanosis, superficial varicose collateral veins | 2. UFH, 7 LMWH, followed by oral anticoagulation (20), Median duration: 6 months 3/29: pulmonary embolism (secondary UV) 12/29: post thrombotic syndrome (secondary UV) | / |
| Serinken et al, Koohsang J Med Sci, 2010 [27] | Turkey | 1 | 31 | F | Right UV | / | US + CT | Painless swelling in the right anterior side of the neck | LMWH and oral warfarin | / |
| Snijders et al, Eur J Gynaecol Oncol, 2010 [28] | Netherlands | 1 | 52 | F | Right UV | Non-hodgkin’s lymphoma of both ovaries | US + CT | Swelling of the right side of the neck | UFH and oral coumarin (duration not describe) | / |
| Handley et al, Int J Otolaryngol, 2010 [29] | UK | 1 | 30 | M | Right UV vein and sigmoid sinus | Collet-Sicard Syndrome secondary to UV thrombosis | CT + MRI | Right sided neck pain, dysphagia and dysphonia | Not describe | / |
| Leibman et al, J Emerg Med, 2009 [30] | Israel | 1 | 31 | F | Right UV | Ovarian hyperstimulation syndrome | US | Pain and swelling of the right side of the neck | LMWH (duration not describe) | / |
| Author, journal, year [ref] | Country                  | Nb* | Age (F/M) | Thrombosis location | Associated factors | Imaging | Symptoms | Treatment (type and length) | Complication |
|-----------------------------|--------------------------|-----|-----------|---------------------|------------------|---------|----------|-----------------------------|---------------|
| Chlumsky et al., Acta Cardiol, 2009 [31] | Czech Republic           | 1   | 61 M      | Right UV            |                   | US      | Swelling of the right side of the face | LMWH and warfarin for 6 months |
| Pata et al., J Laryngol Otol, 2008 [32] | Turkey                   | 2   | 58, 46 F, M | Left UV, Breast and lung cancer | MRI / CT | Painful swelling of the left side of the neck / Painless mass of the left neck and dyspnea | UFH + oral VKA (duration not described) / No treatment because patient died of cancer |
| Mori et al., Clin Appl Thromb Hemost, 2008 [33] | Japan                    | 1   | 16 F      | Left UV, brachiocephalic and subclavian vein | Primary Mediastinal Large B-Cell lymphoma (Trousseau's syndrome) | CT      | General fatigue and dyspnea | Dalteparin (duration not describe) |
| Kikuchi et al., Br J Radiol, 2004 [34] | Japan                    | 1   | 56 M      | Left UV and external jugular vein |                   | CT + FDG-PET | Swelling around the left parotid gland | (treated with antibiotics) |
| Cheang et al., J Laryngol Otol, 2004 [35] | UK                       | 1   | 42 M      | Bilateral UV, Malignant lymphadenopathy | US + CT | Diffuse swelling and stiffness of the neck | UFH (type and duration not describe) |
| Unsal et al., Eur Arch Otorhinolaryngol, 2003 [36] | Turkey                   | 1   | 48 M      | Right UV, Lung and prostate cancer | US + CT | Pain and swelling of the right side of the neck | UFH and oral coumarin (duration not describe) |
| Khandekar et al., Angiology, 2003 [37] | India                    | 1   | 30 M      | Bilateral UV, Protein S Deficiency | CT | Swelling of face, neck and both upper limbs | Anticoagulation + aspirin 150 mg/day |
| Thomas et al., Blood Coagul Fibrinolysis, 2001 [38] | UK                       | 1   | 29 F      | Right UV, Protein S deficiency | US | Pain of the right side of the neck | UFH and Dalteparin 6000 UI twice daily + aspirin 75 mg and Dalteparin 5000 UI twice daily (duration not describe) |
| Van den Noortgate, Acta Clin Belg, 2000 [39] | Belgium                  | 1   | 88 F      | Right UV, Colorectal adenocarcinoma | US + CT | Pain and swelling of the side of the neck | LMWH and oral anticoagulation (type not describe) for 3 months |
| Todros et al, Hum Reprod, 1999 [40] | Italy                    | 1   | 30 F      | Left UV, Ovarian hyperstimulation syndrome | US | Pain and swelling of the left arm and neck | Heparin (2 weeks) and warfarin (13 weeks) and back to heparin (5 weeks) |
| Kalan et al., J Laryngol Otol, 1996 [41] | UK                       | 1   | 65 M      | Left UV, Squamous cell carcinoma (primary lesion not found) | US + CT | Hoarseness | Heparin (type not describe) for 2 months (stopped because patient died) | Death (related or not to UV thrombosis?) |
Table 1 Case reports and case series of unprovoked internal jugular vein thrombosis (Continued)

| Author, journal, year [ref] | Country | Nb* | Age (F/M) | Thrombosis location | Associated factors | Imaging | Symptoms | Treatment (type and length) | Complication |
|-----------------------------|---------|-----|-----------|---------------------|---------------------|---------|----------|----------------------------|--------------|
| Holland et al., Aust N Z J Surg, 1996 [42] | Australia | 1   | 21 F      | Right IJV           | Antiphospholipid syndrome | CT      | Pain and swelling of the right side of the neck | Heparin (type not describe) and long-term oral warfarin | /            |
| Hines et al., Gynecol Oncol, 1995 [43] | USA     | 1   | 49 F      | Left UV + subclavian vein | Ovarian and endometrial adenocarcinoma | US + CT + MRI | Pain and swelling of the left side of the neck | Heparin + warfarin (duration not describe) | Pulmonary embolism |
| Langlieb et al., Gynecol Oncol, 1992 [44] | USA     | 1   | 46 F      | Left UV              | Leiomyosarcoma of the omentum | CT      | Pain of the left side of the neck | Not describe | Not describe |
| Carrington et al., Postgrad Med J, 1988 [45] | UK      | 2   | 56, 59 F, M | 1 Right UV 1 Left UV | Invasive carcinoid and mesothelioma | CT      | Painful and neck swelling | Heparin and acenocoumarol (duration not describe) | Patient with left UV: extension to the left subclavian vein |
| Kennedy et al., Ann Otol Rhinol Laryngol, 1987 [46] | USA     | 1   | 77 F      | Left UV              | /                   | CT      | Nagging sensation of fullness in the inferior left side of her neck | Heparin (type not describe) for 1 week and oral warfarin for 3 months | /            |

Search results = 197 (on 31.03.2020). Advanced Search Builder: spontaneous OR unprovoked OR idiopathic OR primary AND internal jugular vein thrombosis AND English[lang] Sort by: Best Match. Exclusion criteria: article not directly related to the topic. Exclusion’s criteria: papers non-directly linked with the topic, after death discovery, pediatric cases (< 16 years old), non-English papers NA not assessed, LMWH Low molecular weight heparin, UFH unfractionated heparin, VKA vitamin K anticoagulation

* Number of cases of idiopathic cases
neurological complications. The risk of recurrent IJV thrombosis is unknown since the follow-up of published cases was generally interrupted after 3 to 6 months (Table 1).

**Diagnostic testing**

D-dimer concentrations have excellent negative predictive value, even for deep-vein thrombosis of the upper extremities. However, D-dimer concentrations have not been validated with IJV thrombosis because of the lack of prospective outcome trials. Lower D-dimer sensitivity in IJV thrombosis could be an issue, resulting in higher false-negative rates, which could lead to fatal consequences [56, 57].

Performance of imaging to diagnose IJV is unknown. The majority of reports used ultrasonography often completed with CT (21/48; 43.8%). In cases of unprovoked IJV thrombosis, oncological disease and thrombophilia should be screened for since they are more common than in cases of lower-body thrombosis. Indeed, these conditions are frequently associated with IJV thrombosis (Table 2).

Thrombophilia is defined as a hereditary or acquired genetic abnormality predisposing the patient to thromboembolic events [58]. The F5 R506Q gene (the factor V Leiden mutation) is the most common prothrombotic gene mutation in Caucasians [59], affecting 3–7% of this population. It is a gain-of-function mutation in the procoagulant factors. The annual incidence of venous thromboembolism (VTE) in heterozygous carriers of the factor V Leiden mutation is approximately 0.45% [60].

Middeldorp et al. recommended not routinely screening for hereditary thrombophilia as it does not affect most patients’ clinical management, and long-term anticoagulation is generally recommended for patients with unprovoked thrombosis [58]. Thrombophilia screening is only recommended for young (age < 50) patients with a VTE, in cases of recurrent VTE, and in cases involving a family history of VTE [61]. Hereditary thrombophilia does not significantly increase the risk of recurrence (relative risk from 1.4–2.5, depending on the type of mutation [61]), and anticoagulation treatment should be stopped after 3 months in the absence of risk factors such as cancer. American guidelines also propose anticoagulation cessation after 3 months [3]. European guidelines propose individual assessments of the risks of recurrence and major bleeding in order to decide on whether anticoagulation treatment should continue [2]. In the present case, we chose to screen for thrombophilia and cancer because the thrombosis was unprovoked and located in an unusual site. The patient’s borderline age was also taken into account in accordance with an algorithm proposed by Connors [5].

In our review, only 8% (4/48) of patients with IJV thrombosis had an inherited coagulopathy, a low prevalence also seen among Caucasians if patients from Japan, Sri Lanka, India, Jordan, Israel, Turkey, and Saudi Arabia are excluded from the review. Paraneoplastic disease was far more common than inherited coagulopathy, affecting one third of patients (16/48). Thus, an active workup for oncological diseases is of the utmost importance in unprovoked IJV thrombosis.

**Treatment of IJV thrombosis**

There are no specific guidelines for the treatment of IJV thrombosis. Treatment is often based, by analogy, on guidelines [2, 3] for upper-limb thrombosis (Tables 1 and 3). Initial treatment (5–21 days following diagnosis) consists of parenteral therapy with low molecular weight heparin (or unfractionated heparin) with a transition using vitamin K antagonists. The alternative therapy for non-cancer patients is high-dose direct oral anticoagulants. Treatment duration is at least 3 months, with possible long-term anticoagulation depending on the cause of thrombosis [2]. To date, no randomized clinical trials have evaluated anticoagulation for upper extremity deep-vein thrombosis. The only ongoing research is a prospective clinical study assessing oral apixaban for the treatment of upper extremity deep-vein thrombosis (including IJV thrombosis). However, to the best of our knowledge, no results have been published yet [62]. The majority of cases in our literature review used unfractionated heparin (26/40; 65%), usually in association with an oral anticoagulant (19/40; 47.5%). Treatment duration varied from 2 weeks to 6 months for non-paraneoplastic cases (Table 3).

**Follow-up of IJV thrombosis**

No specific guidelines exist for IJV thrombosis follow-up. Gbaguidi et al. used a venous ultrasound scan at three and 6 months. Boedeker et al. [55] proposed an ultrasound scan each month until 6 months of follow-up.

The management of internal jugular vein thrombosis is heterogenous and currently based on the management

---

**Table 2 Etiologies of patients (N = 48) diagnosed with unprovoked IJV (based on a literature review)**

| Etiology                        | Number (%) |
|--------------------------------|------------|
| Idiopathic                     | 17 (35.4)  |
| Paraneoplastic disease         | 16 (33.3)  |
| Coagulopathy                   | 4 (8.3)    |
| Ovarian hyperstimulation syndrome (OHS) | 2 (4.2) |
| Antiphospholipid syndrome      | 2 (4.2)    |
| Other causes                   | 7 (14.6)   |

---

Paynard et al. *Thrombosis Journal* (2021) 19:2
Table 3 Patient characteristics from the literature review (see text for details)

| Characteristic          | Count | Percentage |
|-------------------------|-------|------------|
| Median age              | 51 years old (16–88 y.o.) |
| Sex                     | F: 26/48 (54.2%) | M: 16/48 (33.3%) | Unknown: 6/48 (12.5%) |
| Number of countries     | 17    |
| Modality of diagnostic imaging | US: 7/48 (14.6%) | CT: 11/48 (22.9%) | US + CT: 19/48 (39.5%) | US + MRI: 2/48 (4.2%) | US + CT + MRI: 2/48 (4.2%) |
| Other or unknown modality | 1/48 (2%) |
| Type of treatment       | Heparin only: 7/40 (17.5%) | Heparin + oral anticoagulant: 19/40 (47.5%) | Oral anticoagulant only: 3/40 (7.5%) | Other or unknown: 11/40 (27.5%) |
| Type of oral anticoagulant | Vitamin K antagonists: 18/22 (81.8%) | Direct oral anticoagulants: 3/22 (13.6%) | Unknown: 1/22 (4.6%) |
| Treatment duration      | 3 months: 3/48 (6.25%) | 6 months: 3/48 (6.25%) | Long-term: 5/48 (10.4%) | Other: 4/48 (8.3%) |
| Complications           | Pulmonary embolism: 3/48 (6.25%) | Neurological complication: 0/48 (0%) | Recurrent thrombosis: 2/48 (4.15%) | Extension of thrombosis: 1/48 (2.1%) | No complication: 42/48 (87.5%) |

Abbreviations: F female, M male, US ultrasound, CT computed tomography, MRI magnetic resonance imaging

of lower extremity deep-vein thrombosis, with a low rate of complications. The lack of guidelines and large series means that the modalities of diagnosis and treatment type and duration are variable. Given the low prevalence of IJV thrombosis, large, randomized studies would be hard to carry out. Data from our literature review suggest that treatments could tend towards those used for lower limb deep-vein thrombosis, but that the modalities of diagnosis and the duration of treatment and follow-up should be clarified.

Abbreviations

ARDS: Acute respiratory distress syndrome; BIO: Bowel inflammatory disease; COPD: Chronic obstructive pulmonary disease; CT: Computed tomography; ENT: Ear, nose, and throat; IJV: Internal jugular vein; Jo1: Antistriadiyl transferase antibodies; MRI: Magnetic resonance imaging; NSCLC: Non-small cell lung cancer; OHS: Ovarian hyperstimulation syndrome; RNP: Antinucleoprotein antibodies; SSA: Anti-Smith’s syndrome type A antibodies; SSB: Anti-Smith’s syndrome type B antibodies; Scl70: Anti-scleroderma antibodies; Sm: Anti-Smith antibodies; US: Ultrasound; VTE: Venous thromboembolism

Acknowledgements

None.

Authors’ contributions

LP contributed significantly to conceptualization, investigation, writing the original draft, reviewing, and editing. UI and JD contributed to data analysis, resources, visualization, and validation. GJ contributed significantly to conceptualization, validation and supervision, project administration, reviewing, and editing. All authors approved the submitted version.

Funding

No funding to declare.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Consent for publication

The patient provided her written informed consent for the case report to be published.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière 45, CH-2000 Neuchâtel, Switzerland. 2Department of Internal Medicine, University of Lausanne, Lausanne, Switzerland. 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 4Department of Internal Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland.

Received: 30 August 2020 Accepted: 29 October 2020

Published online: 06 January 2021

References

1. Raskob GE, Anghchaisuksit P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363–71.
2. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208–18.
3. Kearon C, Akil EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S–965S.
4. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care Res. 2002;47:434–44.
5. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377:1177–87.
6. Lip GYH, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.
7. Algoblan D, AlAitah L, Alotaibi AM. Internal Jugular and Subclavian Vein Thrombosis in a Post-Liver Transplant Patient. Cureus. 2020;12:e6557.
8. Pratt DN, Patterson KC, Quin K. Venous thrombosis after nitrous oxide abuse, a case report. J Thromb Thrombolysis. 2020;49:501–3.
9. Agrawal A, Bajaj D, Ruben M, et al. Idiopathic Internal Jugular Vein and Subclavian Vein Thrombosis: A Rare Case Report. Cureus. 2019;11:e4005.
60. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128:15–20.

61. Pruthi RK. Optimal utilization of thrombophilia testing. Int J Lab Hematol. 2017;39:104–10.

62. Woller SC, Stevens SM, Johnson SA, et al. Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT): Methods of a prospective single-arm management study. Res Pract Thromb Haemost 2019;3:340–48.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.